Literature DB >> 31765296

Flow Diverters for Intracranial Aneurysms: The DIVERSION National Prospective Cohort Study.

Benjamin Gory1, Jerome Berge2, Alain Bonafé3, Laurent Pierot4, Laurent Spelle5, Michel Piotin6, Alessandra Biondi7, Christophe Cognard8, Charbel Mounayer9, Nader Sourour10, Charlotte Barbier11, Hubert Desal12, Denis Herbreteau13, Emmanuel Chabert14, Hervé Brunel15, Frédéric Ricolfi16, René Anxionnat1, Evelyne Decullier17, Laure Huot17, Francis Turjman18.   

Abstract

Background and Purpose- Flow diverters are used for endovascular therapy of intracranial aneurysms. We did a nationwide prospective study to investigate the safety and effectiveness of flow diversion at 12 months. Methods- DIVERSION was a national prospective cohort study including all flow diverters placement between October 2012 and February 2014 in France. The primary end point was the event-free survival rate at 12 months, defined as the occurrence of morbidity (intracranial hemorrhage, ischemic stroke, noncerebral hemorrhage, or neurological deficit due to mass effect), retreatment, or death within 12 months post-treatment. A quality control was carried out on 100% of the collected data and of at least 10% of the included patients in each center, chosen at random. All reported serious events were adjudicated by an independent Data Safety and Monitoring Board. Satisfactory occlusion was defined as 3 or 4 on Kamran scale by an independent imaging core laboratory at 12 months. Results- We enrolled 398 patients harboring 477 intracranial aneurysms. At least 1 morbidity-mortality event was noted in 95 of 408 interventions representing an event-free survival rate of 75.7% (95% CI, 71.1-79.7). The rate of permanent-related serious events and mortality was 5.9% and 1.2% at 12 months, respectively. Multivariate analysis showed that high baseline blood pressure (hazard ratio, 2.54; 95% CI, 1.35-4.79; P=0.039), diabetes mellitus (hazard ratio, 3.70; 95% CI, 1.60-8.6; P=0.0022), and larger aneurysms (hazard ratio, 1.07; 95% CI, 1.04-1.11; P<0.0001) were associated with the occurrence of a neurological deficit. The satisfactory occlusion rate at 12 months was 79.9%, and the absence of high baseline blood pressure (odds ratio, 2.01; 95% CI, 1.12-3.71; P=0.0193) and postprocedural satisfactory occlusion (odds ratio, 2.75; 95% CI, 1.49-5.09; P=0.0012) were associated with a 12-month satisfactory occlusion. Conclusions- A satisfactory occlusion was achieved in almost 80% of cases after flow diverter treatment with a permanent-related serious event and mortality rates of 5.9% and 1.2% at 12 months, respectively.

Entities:  

Keywords:  humans; intracranial aneurysm; odds ratio; quality control; stents

Mesh:

Year:  2019        PMID: 31765296     DOI: 10.1161/STROKEAHA.119.024722

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Outcome of flow diverter placement for intracranial aneurysm with dual antiplatelet therapy and oral anticoagulant therapy.

Authors:  Takashi Fujii; Hidenori Oishi; Kohsuke Teranishi; Kenji Yatomi; Kazumoto Suzuki; Hajime Arai
Journal:  Interv Neuroradiol       Date:  2020-07-29       Impact factor: 1.610

2.  Pipeline Embolization device for intracranial aneurysms in a large Chinese cohort: factors related to aneurysm occlusion.

Authors:  Bin Luo; Huibin Kang; Hongqi Zhang; Tianxiao Li; Jianmin Liu; Donglei Song; Yuanli Zhao; Sheng Guan; Aisha Maimaitili; Yunyan Wang; Wenfeng Feng; Yang Wang; Jieqing Wan; Guohua Mao; Huaizhang Shi; Xinjian Yang
Journal:  Ther Adv Neurol Disord       Date:  2020-11-02       Impact factor: 6.570

Review 3.  Surpass Evolve Flow Diverter for the Treatment of Intracranial Aneurysm: A Systematic Review.

Authors:  Rania Issa; Zahrah Al-Homedi; Dawood Hasan Syed; Waseem Aziz; Basem Al-Omari
Journal:  Brain Sci       Date:  2022-06-20

4.  Derivo embolization device in the treatment of unruptured intracranial aneurysms: a prospective multicenter study.

Authors:  Christian A Taschner; Christian Paul Stracke; Franziska Dorn; Krzysztof Bartosz Kadziolka; Kornelia Kreiser; László Solymosi; Mirko Pham; Jan Hendrik Buhk; Bernd Turowski; Wolfgang Reith; Samer Elsheikh; Stephan Meckel; Hendrik Janssen; Alexander Hammer; Oliver Beuing; Olav Jansen; Horst Urbach; Michael Knauth; Carolin Jenkner; René Chapot
Journal:  J Neurointerv Surg       Date:  2020-09-08       Impact factor: 5.836

5.  Possibility of Worsening Flow Diversion Effect Due to Morphological Changes of a Stented Artery With Multiple Overlapping Stents for Partially Thrombosed Vertebral Artery Aneurysms.

Authors:  Tomoaki Suzuki; Hitoshi Hasegawa; Kazuhiro Ando; Kouhei Shibuya; Haruhiko Takahashi; Shoji Saito; Makoto Oishi; Yukihiko Fujii
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

6.  A novel score for evaluating cerebral aneurysms treated with flow diversion: 4F-flow diversion predictive score.

Authors:  Huibin Kang; Bin Luo; Jian Liu; Anxin Wang; Hongqi Zhang; Tianxiao Li; Donglei Song; Yuanli Zhao; Sheng Guan; Yunyan Wang; Wenfeng Feng; Yang Wang; Huaizhang Shi; Jianmin Liu; Xinjian Yang
Journal:  Ther Adv Neurol Disord       Date:  2021-08-19       Impact factor: 6.570

7.  Hemodynamic analysis and implantation strategies of delayed intracranial aneurysm rupture after flow diverter treatment.

Authors:  Shiyao Chen; Bin Bai; Nan Lv; Yunzhang Cheng; Bin Ji
Journal:  Ann Transl Med       Date:  2021-12

8.  Vascular Response on a Novel Fibrin-Based Coated Flow Diverter.

Authors:  Giorgio Cattaneo; Christoph Brochhausen; Ruben Mühl-Benninghaus; Frederik Fries; Mara Kießling; Toshiki Tomori; Stefanie Krajewski; Andreas Simgen; Sabina Bauer; Natascha Hey; Eduard Brynda; Johanka Taborska; Tomáš Riedel; Wolfgang Reith
Journal:  Cardiovasc Intervent Radiol       Date:  2021-12-16       Impact factor: 2.740

9.  Critical Angiographic and Sonographic Analysis of Intra Aneurysmal and Downstream Hemodynamic Changes After Flow Diversion.

Authors:  Radoslav Raychev; Stanimir Sirakov; Alexander Sirakov; Hamidreza Saber; Fernando Vinuela; Reza Jahan; May Nour; Viktor Szeder; Geoffrey Colby; Gary Duckwiler; Satoshi Tateshima
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.